New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency:

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

Published Date: May 2009

Published By: Datamonitor

Page Count: 264

Order Code: R313-51599

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Search Inside
this Report

Similar
Products

CHAPTER 1 EXECUTIVE SUMMARY: Scope of the report; Methodology for primary and secondary research; Primary research; Secondary research; Key findings
CHAPTER 2 OVERVIEW OF TODAY'S R&D LANDSCAPE: Current barriers to R&D optimization; How are pharma companies improving R&D?; Rivals move to collaborate on R&D; Enlight Biosciences: a partnership dedicated to technological innovation in R&D; Companies must be careful not to stifle innovation through M&A; Two key types of restructuring are available to Pharma; Refocusing R&D onto biologics will increase efficiency
CHAPTER 3 ANALYSIS OF MEDTRACK PIPELINE AND DEALS DATABASES: Product pipelines grow while deal making activity declines; Analysis of pipeline candidates by therapy area and indication indicate an increased focus on niche markets; The big four tumors are the most popular indications for solid tumors; Molecular targeted therapies are leading a paradigm shift in oncology; Antibacterial, antifungal and antiviral pipelines all demonstrate strong growth; Novel pipeline antibacterial drugs target niche markets; Antifungal drug discovery is driven by new patient groups; CNS continues to be a thriving market despite generic competition; Fibromyalgia drug development drives growth in pipeline drugs for pain; Antidepressant drug development drives the psychiatry pipeline forward; Low levels of innovation hampers the growth of the cardiovascular market; Ophthalmology had the largest percentage increase in number of drug candidates in clinical development; Substance abuse saw a steep rise in Phase I drugs, but a decline in other stages of development; Majority of Big Pharma have expanded their pipeline portfolios since 2006; Genentech and Bristol-Myers Squibb have shown a significant jump in pipeline candidates; Genentech's innovative approach spurs an enviable pipeline; Bristol-Myers Squibb's strong pipeline is attributed to its externalization strategy; Wyeth, GlaxoSmithKline and Johnson & Johnson saw a decline in their number of pipeline candidates; Wyeth is experiencing a decline in number of drug candidates due to discontinuations; GlaxoSmithKline must increase its R&D productivity to sustain future growth; Johnson & Johnson needs to bolster its early and mid-stage pipeline; Daiichi Sankyo boosts its early-stage pipeline through externalizations; Recent mergers will sharpen R&D structure; Pfizer acquired Wyeth in an effort to diversify its pipeline; Merck & Co's purchase of Schering-Plough provides R&D synergy and the addition of new therapy areas; Roche acquired the remaining stake in Genentech to foster R&D in areas of high growth; Early-stage co-development deals remain the most popular deal type; Early-stage partnerships are the most popular R&D deal type, but have also seen the steepest decline in recent years; Co-development deals are most common among earlier-stage companies as well as the top 50 pharma companies
CHAPTER 4 BIBLIOGRAPHY: Publications and online articles; Datamonitor resources
APPENDIX
List of Tables: Table 1: Most popular targets in for drugs in development, 2009
List of Figures: Figure 1: The R&D process is failing somewhere between initial innovation and market approval; Figure 2: Reasons why pipeline drug candidates are dropped, 2009; Figure 3: Niche, specialty care markets offer Pharma the greatest growth potential; Figure 4: Restructuring Big Pharma R&D operations to increase productivity; Figure 5: Biologics will sharpen the focus of the R&D pipeline; Figure 6: Biologics are changing the emphasis of the value chain; Figure 7: The greatest number of pipeline candidates are in preclinical and Phase II development, this corresponds to the stages showing the greatest deal activity, 2006-Q1 2009; Figure 8: Number of US licensing deals valued at $0-50m entered into by the top 20 pharma companies, Q1 2006-Q3 2008; Figure 9: Change (%) in number of pipeline candidates, Q1 2009 versus 2006; Figure 10: Pipeline candidates by therapy area and indication, 2006-Q1 2009; Figure 11: Change in number of pipeline deals by therapy area, 2008 versus 2006; Figure 12: Number of pipeline candidates versus deals according to therapy area, 2006-Q1 2009; Figure 13: Level of R&D interest and unmet need for four solid tumors, 2008; Figure 14: Clinical unmet needs for the main cardiovascular indications; Figure 15: Vaccines have high entry barriers for generic companies; Figure 16: Number of pipeline candidates (preclinical and Phase I-III) and number of deals for the top 10 pharma companies, 2006-Q1 2009; Figure 17: Change (%) in number of pipeline candidates, Q1 2009 versus 2006; Figure 18: Origins of Bristol-Myers Squibb's product portfolio (2008) and selected key products; Figure 19: How externalization is supplementing Daiichi Sankyo's oncology pipeline; Figure 20: Pfizer, Wyeth and combined Pfizer-Wyeth molecule type and therapy area configurations (% of Rx sales), 2008; Figure 21: Merck & Co, Schering-Plough and combined Merck-Schering-Plough molecule type configuration (% of Rx sales), 2008; Figure 22: Trends in sources and partners for pipeline drug deals in the pharma industry, 2006-08; Figure 23: Trends in the source: partner mix for pipeline drug deal-making, 2006-08; Figure 24: The most common pipeline deal types (2006-08) have been co-development deals although these are now declining; Figure 25: Top 10 pipeline drug deal types by partner: source mix, 2006-08; Figure 26: Trends in number of pipeline candidates according to development stage, 2006 - Q1 09; Figure 27: Trends in number of deals according to development stage, 2006-08

	Research Index \| Publishers \| My Account \| Contact Us \| About MindBranch
	Welcome Guest (Login/Register) \| 0 items